Meditope Biosciences develops antibody-based cancer products using a proprietary meditope mAb linker technology that can turn any monoclonal antibody into a site-specific “Lego-like” system. The platform enables attachment and detachment of drugs without chemical conjugation, producing memAb (meditope-enabled mAb) products intended to improve therapeutic efficacy and simplify manufacturing. The technology was discovered at City of Hope and is positioned as an alternative to existing antibody‑drug conjugate linker technologies. The company says the approach is site-directed, highly efficient, and offers flexibility for therapeutic and diagnostic applications. Meditope has expanded its leadership team with Elisabeth Gardiner, Ph.D., as chief scientific officer and is led by president and CEO Stephanie Hsieh. The company plans to advance the platform into the clinic and pursue development partnerships to establish a leadership position in next-generation antibody linker technology.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2013